SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001404644-24-000043
Filing Date
2024-04-26
Accepted
2024-04-26 14:33:12
Documents
22
Period of Report
2024-04-26

Document Format Files

Seq Description Document Type Size
1 DEF 14A ngne-20240426.htm   iXBRL DEF 14A 612469
6 ngne-20240426_g1.jpg GRAPHIC 7862
7 ngne-20240426_g2.jpg GRAPHIC 7804
8 ngne-20240426_g3.jpg GRAPHIC 15189
9 ngne-20240426_g4.jpg GRAPHIC 9455
10 ngne-20240426_g5.jpg GRAPHIC 263851
11 ngne-20240426_g6.jpg GRAPHIC 343647
12 ngne-20240426_g7.jpg GRAPHIC 170843
13 ngne-20240426_g8.jpg GRAPHIC 248860
  Complete submission text file 0001404644-24-000043.txt   3462223

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT ngne-20240426.xsd EX-101.SCH 2647
3 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT ngne-20240426_def.xml EX-101.DEF 3037
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT ngne-20240426_lab.xml EX-101.LAB 3463
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT ngne-20240426_pre.xml EX-101.PRE 2089
25 EXTRACTED XBRL INSTANCE DOCUMENT ngne-20240426_htm.xml XML 73673
Mailing Address 535 W 24TH STREET 5TH FLOOR NEW YORK NY 10011
Business Address 535 W 24TH STREET 5TH FLOOR NEW YORK NY 10011 (877) 237-5020
Neurogene Inc. (Filer) CIK: 0001404644 (see all company filings)

IRS No.: 980542593 | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-36327 | Film No.: 24882222
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)